Maloney Lauds Congressional Approval of Sunscreen Innovation Act
Washington, DC. Congresswoman Carolyn Maloney (NY-12), co-chair of the Congressional Skin Cancer Caucus, lauded the unanimous House approval of the Sunscreen Innovation Act (S. 2141), bipartisan legislation to pave the way for more effective sunscreen products. Maloney was a cosponsor of the House version, H.R. 4250.
“There is no reason that U.S. consumers should not have access to the most effective products to prevent harmful sun exposure, and I’m proud that Congress was able to work across the aisle this year to pass this important bill,” said Rep. Maloney. “With five million Americans treated for skin cancer each year, we can’t leave consumers waiting a decade or more for new products that are already used widely in Europe and Canada. I’m pleased that this bill will expedite the FDA approval process for these ingredients and hope that the President will sign it into law.”
The Sunscreen Innovation Act (S. 2141/H.R. 4250) establishes a new, expedited approval process for over-the-counter sunscreen ingredients that have been approved for use in other markets such as the E.U. and Canada. Eight such ingredients have been pending FDA approval since 2002.
Rep. Maloney has been a national leader on skin cancer prevention, and founded the Congressional Skin Cancer Caucus in 2013 with bipartisan co-chairs Charles Dent (R-PA), Jim Cooper (D-TN), and Peter Roskam (R-IL).
Maloney’s TAN Act, which passed as part of the FDA Amendments Act of 2007, required the FDA to study the efficacy of warning labels for tanning beds and began the process that led to this reclassification of UV tanning lamps as Class II medical devices, which was finalized in May 2014.
Under the new classification, the FDA will now require black box warning labels on all tanning beds, indicating that the products should not be used by those under the age of 18. Manufacturers will also be required to include additional warnings in their marketing materials and show that their products meet performance testing requirements.
This reclassification was the culmination of a years-long effort by Rep. Maloney. In the 111th and 112th Congresses, Reps. Maloney and Charles Dent (D-PA) introduced the Tanning Bed Cancer Control Act, which would have required the FDA to study the classification of tanning